Regeneron Pharmaceuticals (FRA:RGO) Other Gross PPE : €1,575 Mil (As of Dec. 2024)

View and export this data going back to 1990. Start your Free Trial

What is Regeneron Pharmaceuticals Other Gross PPE?

Regeneron Pharmaceuticals's Other Gross PPE for the quarter that ended in Dec. 2024 was €1,575 Mil.

Regeneron Pharmaceuticals's quarterly Other Gross PPE declined from Jun. 2024 (€4,000 Mil) to Sep. 2024 (€4,000 Mil) and declined from Sep. 2024 (€4,000 Mil) to Dec. 2024 (€1,575 Mil).

Regeneron Pharmaceuticals's annual Other Gross PPE increased from Dec. 2022 (€1,350 Mil) to Dec. 2023 (€1,392 Mil) and increased from Dec. 2023 (€1,392 Mil) to Dec. 2024 (€1,575 Mil).

Regeneron Pharmaceuticals Other Gross PPE Historical Data

The historical data trend for Regeneron Pharmaceuticals's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Other Gross PPE Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Gross PPE

Get a 7-Day Free Trial

936.34

1,185.37

1,349.54

1,392.37

1,574.80

Regeneron Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Gross PPE	Get a 7-Day Free Trial															1,392.37	3,887.46	4,000.18	3,999.72	1,574.80

Regeneron Pharmaceuticals Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (FRA:RGO) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico 0R2M:UK RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines